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Abstract
Purpose
Intravenous immunoglobulin (IVIg) products contain various amounts of dimeric IgG com-
plexes. Current insights into the possible biological activities of these dimers remain contro-
versial, and both immunemodulating and immune-activating effects have been reported.
Here, we analyzed the putative immune-activating effects of dimers isolated from IVIg.
Methods
Dimers isolated from IVIg were purified by high-performance size-exclusion chromatogra-
phy (HP-SEC) and tested for the ability to induce neutrophil degranulation in vitro.
Results
Dimers isolated from IVIg were found to be incapable of inducing in vitro neutrophil degranu-
lation or complement activation, even at concentrations exceeding those expected to be
reached upon administration in patients. These results depend on the removal of artefactual
activation by using 0.1 micron filtration and the use of poloxamer to prevent adsorption of
IgG onto the solid phase.
Conclusions
The data suggest dimeric IgG found in IVIg may bind to Fc-receptors without causing
activation.
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Introduction
IVIg is a pool of IgG derived from thousands of healthy blood donations. IVIg has been used
for more than 30 years in the clinic for immune deficiency and autoimmune diseases treat-
ment[1],[2],[3]. The administration of IVIg, however, is not without side effects. The incidence
of unwanted effects was 12–23% for patients receiving IVIg[4]. The adverse reactions are usu-
ally mild and include headache, chills, fever, flushing, dizziness, malaise, and chest tightness. It
is suggested that the effects are associated with the increase of pro-inflammatory cytokines and
vasodilators triggered by components in IVIg, such as dimers or aggregates during adminstra-
tion[5],[6]. The side effects tend to disappear if the infusion rate is decelerated or by using ste-
roidal anti-inflammatory drugs[7].
In early years, when IgG was fractionated only by cold ethanol fractionation for intramus-
cular administration, large amounts of aggregated IgG (up to 30%) could be detected in the
final product[8]. The aggregation might be a result from hydrophobic contact or elevated tem-
perature during production[9]. This aggregated IgG might induce cross-linking of IgG-Fc
receptors (FcγR) on effector cells and complement cascade activation[10],[11],[12] leading to
the release of pro-inflammatory factors. In the 1990s, additional production steps for intrave-
nous application were introduced to remove aggregates by lowering temperature, pH and eth-
anol concentration, adding proteolytic enzymes such as pepsin and re-fractionating using ion-
exchange chromatography. Since then, the presence of IgG aggregates (larger than dimers) in
IVIg is regulated up to 3% as a requirement for product release[13].
Although the production process of IVIg products has been improved, a substantial amount
of dimer remains present (4–11%) in the final product[14]. These dimers are assumed to be
mainly the result of Fab-Fab interactions between idiotypic and anti-idiotypic antibodies.
[15],[16]. The concentration of dimeric IgG in IVIg is positively related with the number of
donors contributing to the IgG pool, which is thought to raise the number of idiotype-anti-
idiotype combinations[17,18]. Other factors influencing dimerization include concentration,
pH and temperature.
The role of dimers in IVIg during treatment remains elusive. Both beneficial, immunomod-
ulatory effects as well as side effects have been ascribed to the presence of dimers in IVIg. With
respect to the immunomodulatory effects, both in vitro studies in mice and in vitro studies
using human macrophages have suggested an immune-suppressive effect being exerted by
dimeric IgG[19],[20],[21]. Also, a positive correlation was observed between the dimeric IgG
concentration in CIDP patient’s blood post IVIG treatment and clinical improvement.[22] On
the other hand, another study failed to demonstrate enhanced immunosuppressive activity
from dimers in a mouse ITP model.[23] Also, neutrophils isolated from CIVD patients treated
with IVIg have a similar CD16, CD11b and Siglec 9 receptor expression levels and respond
similarly to bacterial stimuli, indicating a lack of phenotypical alterations in circulating neutro-
phils upon IVIg treatment[24]
In contrast to potential beneficial effects, other studies suggest that side effects of IVIg
treatment may in part be the result of neutrophil activation via dimeric IgG. Some studies
using a rat model suggest that dimeric IgG induces a pro-inflammatory effect during IVIg
administration. Dimeric IgG is thought to be responsible for hypotension induced by either
complement-dependent macrophage activation or by FcγR dependent neutrophil activation
[25],[26],[27]. Furthermore, multiple in-vitro studies have indicated that dimeric IgG from
fractioned IVIg increases FcγR mediated oxidation burst and calcium influx of human neutro-
phils[28],[29],[30]. However, as the monomeric IgG fraction also activated neutrophils, albeit
to a lower degree in these studies, this begs the question whether the reported activation by the
dimer may be over-represented or even artefactual. Interestingly, one in vitro study reports
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induction of oxidative burst of neutrophils exposed to ‘low’ (up to 5 mg/mL) concentrations of
IVIg as opposed to high (> 10 mg/mL) concentrations of IVIg[31]
We recently found that commonly used methods for in vitro neutrophil stimulation assays
is actually caused by IgG adhering to the material used to carry out the experiments. This
causes FcγR-crosslinking and activation, explaining how monomeric IgG can cause neutrophil
stimulation in these assays[32]. Furthermore, a method was developed to overcome this limita-
tion. In the present study we assessed the effects of dimeric IgG fractions isolated from IVIg on
neutrophils in vitro. In contrast to previous work, we found that dimeric IgG does not activate
neutrophils even at very high concentrations.
Materials and methods
Antibodies
The IVIg product used in this study was Multigam (CAF-DCF, Belgium). Mabs used were
human CD32a (Novoprotein, NJ) and CD16a (Sino biologicals Inc., China), rabbit anti-
human elastase (Sanquin, the Netherlands), anti-C4-1 monoclonal antibody (mAb) (Sanquin,
the Netherlands).
Reagents
Poloxamer 407 (BASF, the Netherlands), PBS (phosphate buffered saline, 10 mM phosphate,
pH 7.4, 140 mM NaCl, Fresenius Kabi, the Netherlands), IMDM (Iscove’s modified Dulbecco’s
medium, Lonza, Belgium), human elastase (EPC, Missouri, USA), cytochalasin B (Sigma, Ger-
many), N-formyl-Met-Leu-Phe (fMLP; Sigma, Germany). PTG (PBS supplemented with 0.1%
Tween 20 and 0.2% gelatin A), TMB (3,30,5,50 tetramethylbenzamidine, Uptima INTERCHIM,
France), streptavidin horseradish peroxidase (HRP) (Amersham Life Science, UK), 96-well
maxisorb plate (Nunc, Denmark), 96-well polysorb plate (Nunc, Denmark). Biacore buffer
HBS-PE (GE Healthcare, the Netherlands). Ampex red (Molecular Probes/Thermo Fisher Sci-
entific, US), HRP (Sigma, Germany).
Isolation of neutrophils
Peripheral blood from anonymous, healthy volunteers was obtained with informed, written
consent in accordance with Dutch regulations. This study was approved by the Sanquin Ethical
Advisory Board in accordance with the Declaration of Helsinki. Neutrophils were isolated
from with an isotonic Percoll gradient method. Neutrophils were purified from erythrocytes
by lysing erythrocytes with lysis buffer (0.15 M NH4Cl, 0.01 M KHCO3, and 0.1 mM EDTA)
(Verhoeven et al., 1988)[33].
Fractionation of IVIg’s components
IVIg’s components were fractionated with high-performance size-exclusion chromatography
(HP-SEC) on an AKTA system (GE Healthcare, Sweden) using a Hiload 16/600 Superdex 200
column and PBS as elution buffer. The dimeric fraction and monomeric fraction were pooled
and concentrated using Amicon filter centrifuge tubes (Millipore, US) to a concentration of 30
mg/ml. The fractions were dialyzed against IMDM and filtered through a 0.1-μm syringe filter
before being used for further experiments.
Neutrophil activation
Isolated neutrophils of male healthy volunteers were diluted with IMDM media supplemented
with 100 IU/ml (w/v) penicillin, 100μg/ml streptomycin and 5% fetal calf serum (Biowhittaker,
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USA) to a concentration of 4 X 105 cells/ml. 25 μL of cell suspension was incubated with differ-
ent concentrations of 50 μL IVIg fractions (dimeric or monomeric IgG) supplemented with
0.2% poloxamer 407 and IMDM was added to total volume 100 μL. For the experiments with
primed neutrophils, the cells were incubated with cyto B 5 μg/ml for 10 minutes or recombi-
nant human TNF (Active Bioscience, Hamburg, Germany) 25 ng/mL for 30 minutes before
incubation with IVIg fractions. As negative control, neutrophils were incubated with IMDM
media supplemented with 0.2% poloxamer 407; as positive control, 5 μg/ml and 1 nM of cyto-
chalasin B (Sigma, Germany) and fMLP (f-Formyl Met-Leu-Phe; Sigma, Germany), respec-
tively, were added. The cells and stimulant were incubated at 37˚C for 1 hour followed by
centrifugation. The supernatant was taken and directly stored at -20˚C before elastase ELISA
analysis.
Elastase ELISA
Rabbit anti-human elastase (Sanquin, the Netherlands) was diluted in PBS to 1.5 μg/ml. 100 μL
of diluted antibody was added into the wells of a maxisorp 96-well plate and stored overnight
in the fridge (2–8˚C). The 96-well plate was washed 5 times with PBS containing 0.05% Tween
20 (PBS-T) and 100 μL sample (100-fold diluted in PTG buffer) or human elastase standard
(10 ng/ml serially 2-fold diluted in 11 different concentrations) was added. The sample was
incubated at room temperature for 1 hour under gentle shaking and washed 5 times with
PBS-T before incubation with 100 μL biotinylated rabbit anti-human elastase antibody (1 μg/
ml) for another hour. The plate was washed 5 times with PBS-T and further incubated with
100 μL streptavidin HRP (1:1000 in PTG) for 30 minutes. After washing with PBS-T 5 times,
2-fold diluted TMB substrate was added and the reaction was stopped after 13 minutes with 2
N sulfuric acid. The absorbance was read by using a Titertek Multiscan (Flow Laboratories,
Mc Lean, VA) at 450/550 nm. The concentration of elastase was calculated by extrapolating
the absorbance of sample to the standard elastase curve’s absorbance.
Oxidation burst assay
50 μL of 106 neutrophils in HEPES medium was incubated at 37˚C for 30 minutes in black
96-well plates, followed by adding 100 μL reaction solution containing 1 U/ml HRP and 0.05
mM Amplex red freshly prepared in HEPES. Incubation was continued for 5 minutes and
50 μL of samples (IVIg or IVIg fractions in several concentration ranges) or positive controls
(0.04 mM fMLP and 0.04 mM PAF in HEPES medium) were added. Samples were incubated
in a plate reader for 1 hour while oxidation burst was being measured at Ex 535 nm, Em 590
nm and a reading interval 30 s.
Complement activation
The ability of IVIg fractions to activate complement was assessed by combining samples
diluted in veronal buffer supplemented with 0.02% Tween-20 with a serum pool and incubat-
ing the mixtures for 1 hour at 37˚C. Heat-aggregated IgG (pooled human immunoglobulin 10
mg/mL in PBS, incubated at 63˚C for one hour) was used as positive control. Afterwards, pro-
duction of C4b was quantified as a measure for complement activation, as described before
[34]. Briefly, anti-C4-1 mAb was coated onto an ELISA plate. Serial dilutions of the sample
were incubated in the wells for 1 h at 4˚C. After washing, biotinylated polyclonal anti-C4 anti-
bodies were used for detection. A titration curve of normal serum that had been incubated at
37˚C for 7 days in the presence of 0.02% (w/v) NaN3 (NSA) was used as a standard. The level
of activated C4 was expressed as a percentage of the amount of C4b/c present in NSA or as
nmol/l (NSA contains 2500 nmol/l C4b/c).
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PLOS ONE | https://doi.org/10.1371/journal.pone.0195729 April 10, 2018 4 / 12
Surface plasmon resonance
The IVIg fraction and His-tagged human recombinant receptors (CD32a and CD16b) were dia-
lyzed against Biacore buffer and diluted to several concentrations prior to surface plasmon reso-
nance (SPR) analysis. SPR measurements were performed with a Biacore 3000 system (Biacore
AB, the Netherlands) at 25˚C. Anti-histidine antibody (GE Healthcare, the Netherlands), 25 μg/
ml in sodium acetate buffer, pH 4.5 (GE Healthcare, the Netherlands), was coupled covalently to
a CM5 Chip (GE Healthcare, the Netherlands) following activation with EDC (1-ethyl-3-(3
dimethylaminopropyl)-carbodiimide, Sigma, Germany) 0.4 M in water and NHS (N-hydroxy-
succinimide, Sigma, Germany) 0.1 M. To measure the binding of polyclonal IgG to FcγRs,
human recombinant polyHisTag FcγRIIa or human recombinant polyHisTag FcγRIIIb was
diluted in HBS EP buffer (10 mM HEPES, pH 7.4, containing 3.4 mM EDTA, 0.15 mM NaCl,
and 0.005% v/v Tween 20; GE Healthcare, the Netherlands) and injected, followed by the injec-
tion of IgG (0.16 to 5 μM) diluted in HBS EP buffer. A blank run, consisting of injection of recep-
tor followed by injection of buffer, was used as reference run; data was corrected by subtracting
results from this run. The data was processed with BIAevaluation 3.2 RC1 software. Fitting of a
Langmuir binding model to Rmax values vs IgG concentrations was done with GraphPadPrism.
Results
Fractionation of IVIg and characterization of IVIg fractions
The IVIg product used in this study (Multigam) consisted of 5.6±1% dimeric IgG and 94.4
±1% monomeric IgG (Fig 1A). Fractions representing monomeric or dimeric IgG were pooled
as indicated in Fig 1A and concentrated. Immediately after fractionation and concentration,
about 30% of the dimeric fraction had dissociated into monomeric IgG. At the same time ca.
3% of the monomeric fraction seemed to have associated to form dimeric IgG (Fig 1B). We
also analyzed the monomer and dimer content of both fractions after incubation for 1 hour at
37˚C, diluted to 2 mg/mL in IMDM, representing the conditions during incubation with neu-
trophils (Fig 1C). About 60% of IgG in the dimeric fraction remained dimeric, while the com-
position of the monomeric fraction remained similar.
Dimeric and monomeric IgG do not activate neutrophils in vitro
To study the direct effects of dimeric IgG on neutrophils (i.e., dimers in solution), we filtered
samples from monomeric and dimeric fractions of IVIg (at concentrations between 0.3 and 5
mg/mL) with an 0.1 micron filter, and used poloxamer to prevent neutrophil activation by sur-
face-coated IgG, as described before[35]. None of the fractions caused degranulation of neu-
trophils (Fig 2A). By contrast, using a protocol where filtration and the use of poloxamer was
omitted, degranulation was observed for both dimeric as well as monomeric fractions (Fig 2B).
When using poloxamer, but omitting the filtration step, we never observed activation with
IVIg, but did sometimes observe activation with the dimeric fraction, and to a lesser extent
with the monomeric fraction. IgG coated onto a solid surface also resulted in activation of neu-
trophils (Fig 2C). Degranulation by IVIg fractions was also assessed for neutrophils that were
primed with either cytochalasin B or TNF, to facilitate degranulation. However, even under
these conditions, neither a clear neutrophil degranulation (Fig 2D and 2E) nor induction of an
oxidative burst (Fig 2F) was observed.
Complement activation
Besides crosslinking of FcγRs induced by immune complexes, antibodies can activate comple-
ment. Higher order IgG multimers or aggregates have increased affinity for C1q, with an
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optimum for hexameric IgG. Minimal complement activation was seen as C4b/c from
the monomer or dimer fraction or the unfractionated IVIg, except after heat aggregation
(Fig 3).
Fig 1. Fractionation of IVIg. Fresh IVIg was injected onto a HP-SEC column and elution profiles were recorded at
215 nm. Dimeric IgG was separated from monomeric IgG; a representative chromatogram is shown in (a). Each
fraction was collected separately and further analyzed with an analytical HP-SEC column. Dimeric IgG partially
dissociated to monomer, whereas only small amounts of monomeric IgG associated to form dimer (b). The fractions
were incubated at 37˚C for 1 hour to resemble condition in neutrophil activation experiment. The composition each
fraction was analyzed with an analytical HP-SEC column (c). Error bars indicate mean ± SD.
https://doi.org/10.1371/journal.pone.0195729.g001
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Apparent binding affinity to FcγRIIa and FcγRIIIb of dimer fraction is
higher than that of monomer fraction
We also analyzed the binding of monomeric and dimeric IgG fraction to C-terminally His-
tagged FcγRIIa and FcγRIIIb, mimicking their natural orientation in the neutrophil mem-
brane. The FcγRs were first allowed to bind to anti-His-coupled biosensor chips, and their
binding to the IgG fractions was assessed by SPR. The SPR data indicate that dimeric IgG had
a higher apparent affinity to both FcγRIIa and FcγRIIIb compared to monomeric IgG (Fig 4).
Discussion
Despite a long history of IVIg in the treatment of immune deficient and autoimmune disor-
ders, the role of dimeric IgG in IVIg remains elusive. Immune complexes, including dimers,
are generally perceived as unwanted due to their potential to induce inflammation. However,
the present study suggests that dimers derived from IVIg are poor activators of both resting
and primed neutrophils as well as complement, even at or exceeding the high concentrations
associated with IVIg treatment.
Study of the effects of IVIg and its fractions in in vitro assays is complicated, because very
high concentrations of IgG are required to resemble the in vivo situation upon administration
of IVIg, i.e., a range of ca. 1–10 mg/mL. These very high concentrations easily result in variable
Fig 2. Neutrophil activation by IVIg and fractions thereof. Neutrophil activation, measured as elastase release of resting neutrophils, induced by filtered IVIg fractions
at concentrations between 0.3 and 5 mg/mL in the presence of poloxamer (a), or using a previously established protocol without filtration and poloxamer (b). As a
positive control, neutrophils were also stimulated by coated IgG, which leads to more than 80% degranulation at concentrations as low as 0.5 mg/mL (c). Activation of
primed neutrophils using cytochalacin B (d) or TNF (e) by filtered IVIg fractions in the presence of poloxamer. Similarly, oxidation burst was evaluated in the presence
of filtered IVIg fractions in the presence of poloxamer (f). One-way ANOVA (a, d, e, f) or Student’s t test (b, c);  p< 0.05,  p< 0.01,  p< 0.001.
https://doi.org/10.1371/journal.pone.0195729.g002
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degrees of IgG absorbing to solid surfaces like microtiter plates, even in the presence of abun-
dant amounts of other proteins (albumin). The absorbed IgG can induce activation of cells
such as neutrophils, the most abundant white blood cell present in human blood[35].
Previously we found that poloxamer can eliminate neutrophil activation at these high IgG
concentrations by preventing IgG adsorption in test tubes[36],[35]. Polysorbate is also effective
but will lead to cell lysis. Here, we found that in addition to the use of poloxamer, 0.1 micron
filtration of fractionated dimers and monomers was necessary to completely prevent neutro-
phil activation. This filtration step did not significantly affect the overall IgG concentration or
dimer content of the fractions. One possible explanation for the activation that was sometimes
observed with the unfiltered fractionated material is that small amounts of aggregates were
formed during the process. The amounts of aggregates likely differ between successive frac-
tionations, resulting in different degrees of activation. Preliminary analyses using nanoparticle
tracking analysis (NTA) revealed the presence of particles in the range of 150–300 nm pre-
dominantly in the dimer fraction, which indeed could be effectively removed to undetectable
levels by filtration through a 0.1-μm filter without significantly affecting the dimer and mono-
mer composition of the fractions. Nevertheless, this does not prove that these aggregates are
causing the activation.
Our results are in line with studies showing a stronger induction of neutrophil degranula-
tion by insoluble immune complexes compared to (smaller) soluble complexes[37],[38],[39].
An IgG dimer is the smallest possible immune complex (containing two IgG molecules) and
therefore the least effective in cross-linking multiple Fc receptor molecules. Likewise, recruit-
ing the C1 complex probably requires more than two IgG molecules, or preferentially hexam-
ers spatially organized through Fc-Fc interactions, allowing for maximal C1q interaction.
Perhaps not surprisingly, our experiments revealed that binding affinity/avidity of dimeric
IgG to FcγR is higher than that of monomeric IgG. Although the exact receptor density on the
Fig 3. Complement activation by IVIg fractions. Detection of fluid-phase complement activation by measuring C4b/
c in serum incubated at 37˚C together with IVIg, dimeric, monomeric fraction and heated IgG (aggregates), or no
stimulus, incubated at 37˚C or on ice. One-way ANOVA;  p< 0.001.
https://doi.org/10.1371/journal.pone.0195729.g003
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biosensor surface may not be representative of densities on the actual cellular surface, we did
do our best to simulate the actual orientation, by attaching the receptors to the SPR biosensor
through a C-terminal His-tag. However, in contrast to a cell membrane, there is no possibility
for lateral movement of the receptor molecules. Therefore, these binding studies cannot reveal
to which extent dimers from IVIg may bind more efficiently as compared to monomeric IgG.
Nevertheless, it is likely that dimers also bind more avidly to Fc receptors on effector cells[40].
Given their poor ability to activate, as shown in this study, this suggests that dimers might be
more potent inhibitors of Fc receptor-mediated effector mechanisms, thereby contributing to
the anti-inflammatory effects of IVIg. This is in line with a recent study demonstrating recom-
binant Fc trimers to be effective inhibitors of Fc receptor-mediated monocyte or neutrophil
activation[41].
Indeed, Teeling et al. reported the prevention of platelet clearance by a dimeric IVIg frac-
tion in rats[20]. However, to obtain dimeric IgG, reconstituted freeze-dried IVIg was stored
at 4˚C until the concentration of dimeric IgG gradually increased. This method probably
results in formation of larger aggregates as well as dimers, and larger IgG complexes might
have (disproportionally) contributed to the observed effects. In addition to this, chemically sta-
bilized dimerized IVIg was found to be more effective in preventing idiopathic thrombocyto-
penic purpura (ITP) in a mouse model[21]. On the other hand, another study reported no
clear correlation between the dimer content of human immunoglobulin products and their
Fig 4. Binding to FcγR by IVIg fractions. Sensograms of the binding of dimeric fraction (a,d) and monomeric fraction
(b,e) to FcγRIIIb (a-b) or FcγRIIa (d-e) coupled to a biosensor chip through its C-terminal His-tag. Steady state apparent
affinities calculated from the sensogram data were obtained from fitting a Langmuir binding model as shown in the inset
panels, to calculate the apparent Kd values to FcγRIIIb (c) or FcγRIIa (f). One-way ANOVA;  p< 0.01.
https://doi.org/10.1371/journal.pone.0195729.g004
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effectiveness in ITP mouse models[23]. One factor that complicates these studies is the
dynamic and reversible nature of the dimerization process in these products[18], with temper-
ature, concentration, pH, and ionic strength all affecting the amounts of dimers. This implies
that following injection into mice, the amounts of dimers may change, which might explain
the apparent lack of correlation. Furthermore, IVIg may contain autoantibodies to neutrophil
proteins including siglec-9 that are highly enriched in dimeric fractions, and have been sug-
gested to also contribute to an anti-inflammatory effect of IVIg [42]
The experiments in this study were performed using isolated neutrophils, which potentially
influences the results. However, neutrophils isolated by density gradient centrifugation has
been reported to become more prone to degranulation,[43] which would only strengthen our
conclusion that dimers are incapable of triggering degranulation.
In conclusion, dimeric IgG from IVIg is a poor trigger of neutrophil degranulation and
complement activation. The results from this study do not support the notion that dimeric
IgG in IVIg is a major cause of adverse reactions.
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